BidaskClub upgraded shares of Sinovac Biotech (NASDAQ:SVA) from a hold rating to a buy rating in a research report sent to investors on Tuesday.
Sinovac Biotech (SVA) opened at $8.65 on Tuesday. Sinovac Biotech has a 52-week low of $4.60 and a 52-week high of $8.70. The company has a market capitalization of $493.22, a PE ratio of -864.14 and a beta of 0.19.
A number of hedge funds have recently modified their holdings of SVA. State Street Corp lifted its stake in Sinovac Biotech by 18.5% during the second quarter. State Street Corp now owns 49,281 shares of the biopharmaceutical company’s stock worth $333,000 after purchasing an additional 7,711 shares during the last quarter. SG Americas Securities LLC bought a new stake in Sinovac Biotech during the third quarter worth about $163,000. Citadel Advisors LLC lifted its stake in Sinovac Biotech by 189.8% during the third quarter. Citadel Advisors LLC now owns 34,193 shares of the biopharmaceutical company’s stock worth $241,000 after purchasing an additional 22,393 shares during the last quarter. Neumann Advisory Hong Kong Ltd bought a new stake in Sinovac Biotech during the fourth quarter worth about $3,174,000. Finally, Eqis Capital Management Inc. lifted its stake in Sinovac Biotech by 4.6% during the fourth quarter. Eqis Capital Management Inc. now owns 156,492 shares of the biopharmaceutical company’s stock worth $1,233,000 after purchasing an additional 6,953 shares during the last quarter. 12.62% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Sinovac Biotech (SVA) Lifted to “Buy” at BidaskClub” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was stolen and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2018/03/21/sinovac-biotech-sva-lifted-to-buy-at-bidaskclub.html.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
Receive News & Ratings for Sinovac Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech and related companies with MarketBeat.com's FREE daily email newsletter.